Literature DB >> 32762119

Optimal blood pressure for the prevention of hypertensive nephropathy in nondiabetic hypertensive patients in Taiwan.

Ting-Wei Kao1, Chin-Chou Huang2,3,4,5, Jaw-Wen Chen3,4,5,6.   

Abstract

Hypertension is a global health burden. However, clinical reference for the adequate management of blood pressure (BP) to prevent renal injury has yet to be established. Thus, this study aimed to investigate whether optimal control and maintenance of BP at < 140/90, < 130/80, or < 120/70 mmHg could prevent hypertensive nephropathy in nondiabetic hypertensive patients. A single-center observational study of 351 nondiabetic hypertensive patients was conducted in Taiwan. The average age of the participants was 64.0 years, and approximately 57.8% of the participants were men. Kidney function was assessed using estimated glomerular filtration rate (eGFR). The baseline eGFR was 83.8 ± 19.8 mL/min/1.73 m2 . All patients were followed up every 3 months and underwent office BP measurement and blood sampling. Renal events were defined as> 25% and> 50% decline in eGFR. During an average follow-up period of 4.2 ± 2.3 years, a> 25% and> 50% decline in eGFR was noted in 49 and 11 patients, respectively. The Cox regression analysis revealed that a baseline BP ≥ 140/90 mmHg (hazard ratio [HR]: 1.965; 95% confidence interval [CI]: 1.099-3.514, P = 0.023) and ≥ 130/80 mmHg (HR: 2.799; 95% CI: 1.286-6.004, P = 0.009) increased the risk of> 25% decline in eGFR. Moreover, a baseline BP ≥ 140/90 mmHg (HR: 8.120; 95% CI: 1.650-39.956, P = 0.010) and follow-up BP ≥ 140/90 mmHg (HR: 6.402; 95% CI: 1.338-30.637, P = 0.020) increased the risk of> 50% decline in eGFR. In conclusion, a stringent baseline BP < 130/80 mmHg and a follow-up BP < 140/90 mmHg can be considered optimal cutoff values for clinical practice to prevent hypertensive nephropathy. ©2020 Wiley Periodicals LLC.

Entities:  

Keywords:  Chinese; blood pressure; chronic kidney disease; hypertension; nephropathy

Mesh:

Year:  2020        PMID: 32762119      PMCID: PMC8029863          DOI: 10.1111/jch.13956

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  25 in total

Review 1.  Systolic and diastolic blood pressure control in antihypertensive drug trials.

Authors:  Giuseppe Mancia; Guido Grassi
Journal:  J Hypertens       Date:  2002-08       Impact factor: 4.844

2.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

3.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

4.  Risk of developing end-stage renal disease in a cohort of mass screening.

Authors:  K Iseki; C Iseki; Y Ikemiya; K Fukiyama
Journal:  Kidney Int       Date:  1996-03       Impact factor: 10.612

5.  Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland.

Authors:  Melanie K Haroun; Bernard G Jaar; Sandra C Hoffman; George W Comstock; Michael J Klag; Josef Coresh
Journal:  J Am Soc Nephrol       Date:  2003-11       Impact factor: 10.121

6.  Telmisartan, ramipril, or both in patients at high risk for vascular events.

Authors:  Salim Yusuf; Koon K Teo; Janice Pogue; Leanne Dyal; Ingrid Copland; Helmut Schumacher; Gilles Dagenais; Peter Sleight; Craig Anderson
Journal:  N Engl J Med       Date:  2008-03-31       Impact factor: 91.245

7.  Association of Repeated Measurements With Blood Pressure Control in Primary Care.

Authors:  Douglas Einstadter; Shari D Bolen; James E Misak; David S Bar-Shain; Randall D Cebul
Journal:  JAMA Intern Med       Date:  2018-06-01       Impact factor: 21.873

8.  Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial.

Authors:  Ramón C Hermida; Juan J Crespo; Manuel Domínguez-Sardiña; Alfonso Otero; Ana Moyá; María T Ríos; Elvira Sineiro; María C Castiñeira; Pedro A Callejas; Lorenzo Pousa; José L Salgado; Carmen Durán; Juan J Sánchez; José R Fernández; Artemio Mojón; Diana E Ayala
Journal:  Eur Heart J       Date:  2020-12-21       Impact factor: 29.983

9.  The Utility of Repeating Automated Blood Pressure Measurements in the Primary Care Office.

Authors:  Usama A Daimee; Douglas Done; Wan Tang; Xin M Tu; John D Bisognano; William H Bayer
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-08-21       Impact factor: 3.738

10.  Optimal blood pressure for the prevention of hypertensive nephropathy in nondiabetic hypertensive patients in Taiwan.

Authors:  Ting-Wei Kao; Chin-Chou Huang; Jaw-Wen Chen
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-08-06       Impact factor: 3.738

View more
  3 in total

1.  SLC12A3 Variation and Renal Function in Chinese Patients With Hypertension.

Authors:  Chin-Chou Huang; Chia-Min Chung; Chih-Yu Yang; Hsin-Bang Leu; Po-Hsun Huang; Liang-Yu Lin; Tao-Cheng Wu; Shing-Jong Lin; Wen-Harn Pan; Jaw-Wen Chen
Journal:  Front Med (Lausanne)       Date:  2022-06-21

2.  Uric Acid and Impairment of Renal Function in Non-diabetic Hypertensive Patients.

Authors:  Yi-Hsin Hung; Chin-Chou Huang; Liang-Yu Lin; Jaw-Wen Chen
Journal:  Front Med (Lausanne)       Date:  2022-01-24

3.  Optimal blood pressure for the prevention of hypertensive nephropathy in nondiabetic hypertensive patients in Taiwan.

Authors:  Ting-Wei Kao; Chin-Chou Huang; Jaw-Wen Chen
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-08-06       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.